지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.7
- 수록면
- 21 - 29 (9page)
이용수
초록· 키워드
오류제보하기
Purpose: Identification of subgroups of patients who differ in their response to treatment could help to establish which of the best available chemotherapeutic options are best, based on biological activity. In metastatic colorectal cancer (CRC), novel molecular-targeted agents that act on pathways that regulate cell growth, the cell cycle, apoptosis, angiogenesis, and invasion are being developed. Here, we employed an in vitro chemosensitivity assay to evaluate the biological efficacy of conventional monotherapies and combination chemotherapy with targeted drugs. Methods: The chemosensitivities of 12 CRC cell lines to the established regimens FOLFOX (5-fluorouracil [5-FU] ＋ leucovorin ＋ oxaliplatin) and FOLFIRI (5-FU ＋ leucovorin ＋ irinotecan) and to therapy with these regimens in combination with the biologically targeted drugs bevacizumab or cetuximab were comparatively evaluated for their effects on apoptotic and autophagic cell death processes, angiogenesis, and invasion. Results: Each of the chemotherapeutic regimens promoted apoptotic cell death and invasion. All drug regimens caused significantly greater apoptotic cell death with activation of caspase-3 in SW480 cells compared to other cells, effects that were associated with a remarkable reduction in matrix metalloproteinase-9 activity. The FOLFOX regimen more effectively promoted apoptotic cell death, angiogenesis, and invasion than the FOLFIRI regimen. Combination therapy with FOLFOX/FOLFIRI regimen and bevacizumab produced a moderate angiogenesis-blocking effect in most cell lines. Conclusion: The results validate our in vitro chemosensitivity assay, and suggest that it may be applied to help determine adequate regimens in individual CRC patients based on the biological characteristics of their tumors.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
CONFLICTS OF INTEREST
REFERENCES
참고문헌 (30)
참고문헌 신청
1. [학술지(정기간행물)] - Kelly C / 2007 / Chemotherapy in metastatic colorectal cancer / Surg Oncol 16 : 65 ~ 70
2. [학술지(정기간행물)] - Sabharwal A / 2007 / Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future / Expert Rev Anticancer Ther 7 : 477 ~ 487
3. [학술지(정기간행물)] - Tournigand C / 2004 / FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study / J Clin Oncol 22 : 229 ~ 237
4. [학술지(정기간행물)] - Hanahan D / 2000 / The hallmarks of cancer / Cell 100 : 57 ~ 70
5. [학술지(정기간행물)] - Ju JH / 2007 / Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years / Int J Colorectal Dis 22 : 855 ~ 862
2. [학술지(정기간행물)] - Sabharwal A / 2007 / Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future / Expert Rev Anticancer Ther 7 : 477 ~ 487
3. [학술지(정기간행물)] - Tournigand C / 2004 / FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study / J Clin Oncol 22 : 229 ~ 237
4. [학술지(정기간행물)] - Hanahan D / 2000 / The hallmarks of cancer / Cell 100 : 57 ~ 70
5. [학술지(정기간행물)] - Ju JH / 2007 / Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years / Int J Colorectal Dis 22 : 855 ~ 862
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2013-514-003445594